EU officials clash with Chinese firm on drug factory inspection

London – European medicines regulators have issued a notice that an ingredient for a generic brain cancer drug made in China does not meet manufacturing standards, after inspectors were refused entry to a factory run by Jiangsu Yew Pharmaceutical Co. Ltd.

The incident, reported in a published this week on a database maintained by the European Medicines Agency, is the latest example of regulatory problems with bulk pharmaceutical substances manufactured in China.

It follows a scandal over tainted supplies of the widely used heart drug valsartan from Zhejiang Huahai Pharmaceutical, which led to dozens of recalls around the world of finished tablets containing the Chinese product. U.S. officials have also recently recalled porcine thyroid active ingredient from China due to inconsistent quality.

In the latest case, Jiangsu Yew refused to allow a site inspection by Hungarian officials, acting on behalf of Europe’s drug regulatory system. The rebuttal led the EU authorities to determine that its supplies of temozolomide, used to treat brain tumors, did not comply with good manufacturing standards.

The company’s export director Henry Yang told Reuters via email that the inspection was refused because Jiangsu Yew only made an intermediate product, rather than an active pharmaceutical ingredient (API), so an audit was not required.

Manufacturers in China and India supply more than two-thirds of all bulk pharmaceutical substances used in medicines, industry executives estimate, with China accounting for the lion’s share.

In recent years, U.S. and European regulators have increased scrutiny of Asian drug factories following the adulteration of the blood thinner heparin, which sickened hundreds and caused the deaths of at least 81 Americans in 2007 and 2008.

"Monitoring Desk"

RELATED POSTS

246
PM Imran Khan praises Chinese support, says China has been helpful in many areas
0.7 Million jobs likely under CPEC by 2030
Power generation capacity of Port Qasim power plant equivalent to 10 percent of national power generation capacity
CPEC energy projects undergoing rapid construction
China confirms pledging financial assistance to Pakistan
NHA plans construction of sections of CPEC Western Route, project to complete by end of 2019
CPHGC’s Unit 1 successfully synchronized with Pakistan national grid
Chinese Embassy clarifies CPEC debt article
Chinese industrial group to establish ceramics unit in Faisalabad
Chinese Embassy provides details on the latest progress of CPEC
Work on the New Gwadar International Airport, vocational training center and friendship hospital to begin in the first quarter of 2019
Six Pakistani entrepreneurs graduate from UNCTAD, Alibaba’s fellowship
China donates Rs6m more to families of martyred cops
Pakistan coming on track by enhanced export, trade volume with neighboring countries
China says it hopes US can show sincerity on trade

FOLLOW US


About Corridor.pk

Corridor.pk is Pakistan’s leading regional connectivity media & communication/outreach platform, dedicated to profiling and promoting the business activities, news and views on the regionally connected business corridor across OBOR. 

     

Addional Information

 Ethics Policy     Advertise
 Terms & Conditions
 Contact Us